Compare IMNM & ASH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMNM | ASH |
|---|---|---|
| Founded | 2006 | 1924 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Specialty Chemicals |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.4B |
| IPO Year | 2020 | 2016 |
| Metric | IMNM | ASH |
|---|---|---|
| Price | $22.03 | $57.29 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 7 |
| Target Price | $32.80 | ★ $65.57 |
| AVG Volume (30 Days) | 915.1K | ★ 1.1M |
| Earning Date | 05-08-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 3.38% |
| EPS Growth | ★ 51.40 | N/A |
| EPS | N/A | ★ 0.08 |
| Revenue | $6,941,000.00 | ★ $1,824,000,000.00 |
| Revenue This Year | N/A | $2.58 |
| Revenue Next Year | $1,127.34 | $4.28 |
| P/E Ratio | ★ N/A | $714.63 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.96 | $46.30 |
| 52 Week High | $27.65 | $65.65 |
| Indicator | IMNM | ASH |
|---|---|---|
| Relative Strength Index (RSI) | 48.94 | 55.89 |
| Support Level | $19.23 | $53.89 |
| Resistance Level | $23.24 | $57.41 |
| Average True Range (ATR) | 1.27 | 1.87 |
| MACD | -0.05 | 0.29 |
| Stochastic Oscillator | 55.07 | 75.37 |
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.
Ashland Inc. is a specialty materials company serving markets including pharmaceuticals, personal care, food and beverages, coatings, construction, energy, and electronics. It operates through four segments: Life Sciences, Personal Care, Specialty Additives, and Intermediates. Life Sciences contributes the highest revenue, offering functional additives for pharmaceutical and nutrition applications. Personal Care provides ingredients for skin, hair, oral care, and household products, while Specialty Additives supplies performance-enhancing additives for coatings and. Intermediates produce BDO and related derivatives used in polymers, electronics, agriculture, and pharmaceutical applications. The company generates sales across North America, Europe, Asia Pacific, Latin America, and regions.